U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb and bluebird bio Application for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121)

PRINCETON, N.J.,& CAMBRIDGE, Mass.--(BUSINESS WIRE) September 22, 2020 -- Bristol Myers Squibb (NYSE: BMY) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news